@article{7b30dc5a42ad46dbb12d7a484223f258,
title = "Kidney Hemodynamic Effects of Angiotensin Receptor Blockade, Sodium-Glucose Cotransporter-2 Inhibition Alone, and Their Combination: A Crossover Randomized Trial in People With Type 2 Diabetes",
keywords = "Diabetes Mellitus, Type 2/drug therapy, Diabetic Nephropathies/drug therapy, Glucose, Humans, Kidney, Receptors, Angiotensin, Sodium, diabetic kidney disease, sodium glucose cotransporter-2 inhibitor, type 2 diabetes mellitus, angiotensin receptor blocker",
author = "Scholtes, \{Rosalie A.\} and Hesp, \{Anne C.\} and Mosterd, \{Charlotte M.\} and Frank Geurts and Hoorn, \{Ewout J.\} and Touw, \{Daan J.\} and Krebber, \{Merle M.\} and Joles, \{Jaap A.\} and Heerspink, \{Hiddo J.L.\} and \{Van Raalte\}, \{Dani{\"e}l H.\}",
note = "Funding Information: R.A.S., A.C.H., C.M.M., F.G., E.J.H., M.M.K., and J.A.J. report no conflicts. D.H.vR. has acted as a consultant for and received honoraria from Boehringer Ingelheim-Eli Lilly Alliance, Merck, Sanofi, and AstraZeneca, and has received research operating funds from Boehringer Ingelheim-Lilly Diabetes Alliance, AstraZeneca, and Merck. All honoraria are paid to his employer (Amsterdam University Medical Centers, location VUMC). D.J.T. reports grants from ZONMW and Chiesi Pharmaceuticals, as well as fees to his institution from ZONMW and PurelMS. H.J.L.H. has received research support from AbbVie, AstraZeneca, Boehringer Ingelheim, and Janssen, as well as fees to his institution for his participation on advisory boards from Merck, Mitsubishi Tanabe, Janssen, and Mundipharma; for consulting from AbbVie, Retrophin, Boehringer Ingelheim, and Novo Nordisk; and for participation in steering committees from Janssen, Gilead, Bayer, Chinook, and CSL Pharma.",
year = "2022",
month = dec,
day = "13",
doi = "10.1161/CIRCULATIONAHA.122.061033",
language = "English",
volume = "146",
pages = "1895--1897",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams \& Wilkins",
number = "24",
}